Qinghai Spring Medicinal Resources Technology Co., Ltd.

Shanghai Stock Exchange 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue for the year ending December 31, 2023: USD 30.12 M

Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue is USD 30.12 M for the year ending December 31, 2023, a 29.78% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue for the year ending December 31, 2022 was USD 23.21 M, a 15.44% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue for the year ending December 31, 2021 was USD 20.11 M, a 5.62% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue for the year ending December 31, 2020 was USD 19.04 M, a -43.28% change year over year.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Revenue for the year ending December 31, 2019 was USD 33.57 M, a -30.68% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shanghai Stock Exchange: 600381.SS

Qinghai Spring Medicinal Resources Technology Co., Ltd.

CEO	Mr. Xuefeng Zhang
IPO Date	May 8, 2001
Location	China
Headquarters	Xining Eco and Techn Dev Zone
Employees	173
Sector	Materials
Industries Paper & Forest Products Biotechnology Pharmaceuticals

Description

Qinghai Spring Medicinal Resources Technology Co., Ltd. research and development, production, and sale of cordyceps products. It is also involved in the sale of beverages and aquatic products; advertising; and foreign investment business. The company was founded in 2003 and is based in Xining, China.

Key trends

Past 5 years